Evaluation of 99mTc-labeled cyclic RGD dimers: Impact of cyclic RGD peptides and 99mTc chelates on biological properties

Bioconjugate Chemistry

Volumn 23, Issue 3, 2012, Pages 586-595

  Zhou, Yang ^a   Kim, Young Seung ^a   Lu, Xin ^a   Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; ISOMERS; PEPTIDES;

ATHYMIC; BIODISTRIBUTIONS; BIOLOGICAL PROPERTIES; HUMAN BREAST; MACROCYCLICS; NUDE MICE; RGD PEPTIDE; TARGETING CAPABILITY; TUMOR UPTAKE; TUMOR-TARGETING;

TUMORS;

6 HYDRAZINONICOTINYLLYSINE(NICOTINYL) GLYCYLGLYCYLGLYCYLHYDROGLUTAMINE[GLYCYLGLYCYLGLYCYL CYCLO(ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLLYSINE)] (TRICINE) TC 99M; 6 HYDRAZINONICOTINYLLYSINE(NICOTINYL) HYDROGLUTAMINE[CYCLO(ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLLYSINE)] (TRICINE) TC 99M; 6 HYDRAZINONICOTINYLLYSINE(NICOTINYL) POLYETHYLENEGLYCOLGLUTAMINE[POLYETHYLENEGLYCOL CYCLO(ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLLYSINE)] (TRICINE) TC 99M; ARGINYLGLYCYLASPARTIC ACID; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; CHELATING AGENT; CYCLOPEPTIDE; OLIGOPEPTIDE; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; EVALUATION; MOUSE; NONHUMAN; ANIMAL; BREAST TUMOR; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION; XENOGRAFT;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863369224     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200631g     Document Type: Article

References (32)

1. Edwards, D. S., Liu, S., Ziegler, M. C., Harris, A. R., Crocker, A. C., Heminway, S. J., Barrett, J. A., Bridger, G. J., Abrams, M. J., and Higgins, J. D. (1999) RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide conjugated chemotactic peptide for infection imaging Bioconjugate Chem. 10, 884-891 (Pubitemid 29456378)
2. 99mTc-labeled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits Nucl. Med. Commun. 21, 1043-1051
3. 99mTc-Labeling of a hydrazinonictotinamide-conjugated vitronectin receptor antagonist Bioconjugate Chem. 12, 624-629 (Pubitemid 32696237)
4. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer Bioconjugate Chem. 16, 1580-1588 (Pubitemid 41681526)
5. 3 expression Bioconjugate Chem. 17, 1069-1076 (Pubitemid 44162628)
6. 3-positive breast cancer Bioconjugate Chem. 18, 438-446 (Pubitemid 46493515)
7. 99mTc-labeled cyclic RGDfK tetramer Nucl. Med. Biol. 35, 111-121 (Pubitemid 350298246)
8. 99mTc Bioconjugate Chem. 8, 146-154 (Pubitemid 27153287)
9. 99mTc-labeling hydrazones of a hydrazinonicotinamide conjugated cyclic peptide Bioconjugate Chem. 10, 803-807 (Pubitemid 29456367)
10. 2 formulation for DMP444: a new radiopharmaceutical for thrombus imaging J. Pharm. Sci. 90, 114-123 (Pubitemid 32158039)
11. Liu, S., Edwards, D. S., Harris, A. R., Heminway, S. J., and Barrett, J. A. (1999) Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: Synthesis and characterization Inorg. Chem. 38, 1326-1335
12. 99mTc-labeled bioconjugates Bioconjugate Chem. 11, 113-117
13. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals Chem. Rev. 99, 2235-2268
14. 99mTc-labeling of small biomolecules Top. Curr. Chem. 252, 117-153 (Pubitemid 44420847)
15. 99mTc-labeling of small biomolecules Bioconjugate Chem. 14, 720-727 (Pubitemid 36875431)
16. 99mTc-labeling of small biomolecules Bioconjugate Chem. 15, 728-737 (Pubitemid 38981946)
17. 99mTc-labeled radiopharmaceuticals Bioconjugate Chem. 10, 808-814 (Pubitemid 29456368)
18. 99mTc-labeled cyclic RGD dimers with PEG4 linkers Mol. Pharmaceutics 6, 231-245
19. 3 expression Mol. Imaging 10, 386-397
20. 99mTc-labeled cyclic Arginine-Glycine-Aspartic (RGD) dimers with triglycine linkers J. Med. Chem. 51, 7980-7990
21. 3-targeted radiotracer with high tumor uptake and favorable pharmacokinetics Eur. J. Nucl. Med. Mol. Imaging 36, 1874-1884
22. 4 Linkers Bioconjugate Chem. 20, 750-759
23. 99mTc-labeling of cyclic RGD dimers: effects of technetium chelate on tumor uptake and pharmacokinetics Bioconjugate Chem. 20, 1559-1568
24. 3 PET imaging Eur. J. Nucl. Med. Mol. Imaging 36, 947-957
25. 4 linkers Eur. J. Nucl. Med. Mol. Imaging 36, 1296-1307
26. 3-targeted radiotracers: maximizing binding affinity via bivalency Bioconjugate Chem. 20, 2199-2213
27. Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., and Thrall, J. H. (2005) Imaging angiogenesis: applications and potential for drug development J. Natl. Cancer Inst. 97, 172-187 (Pubitemid 40277367)
28. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development? Mol. Cancer Ther. 5, 2624-2633 (Pubitemid 44848989)
29. Niu, G. and Chen, X. (2008) Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R D 9, 351-368
30. Michalski, M. H. and Chen, X. (2011) Molecular imaging in cancer treatment Eur. J. Nucl. Med. Mol. Imaging 38, 358-377
31. Grégoire, V. and Chiti, A. (2011) Molecular imaging in radiotherapy planning for head and neck tumors J. Nucl. Med. 52, 331-334
32. 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time? J. Nucl. Med. 52, 335-337